It is possible that a longer period of follow-up would be required for any differences in HCRU related to therapeutic potency to manifest, and this is a possibility worthy of further study
Although GLP-1 receptor agonists are generally well tolerated in metabolic populations, they are associated with potential side effects such as gastrointestinal discomfort, nausea, and appetite changes
Allergic reactions like eczema or dizziness are also possible
As SGLT2 inhibitor reduces the insulin-to-glucagon ratio by lowering plasma glucose levels, it increases lipolysis and ketogenesis, thereby elevating the risk of DKA [1]
DSIP has been studied in human clinical settings for decades, with research examining its effects on sleep disorders, stress-related insomnia, and recovery in high-demand populations